Brief: Sigilon Therapeutics Receives Orphan Drug Designation For SIG-007 For Treatment Of Fabry Disease
05/03/2021 12:05
March 5 (Reuters) - Sigilon Therapeutics, Inc. SGTX.O :
* SIGILON THERAPEUTICS RECEIVES ORPHAN DRUG DESIGNATION FOR
SIG-007 FOR THE TREATMENT OF FABRY DISEASE
Source text for Eikon: ID:nGNX9h22Jj
Further company coverage: SGTX.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Sigilon Therapeutics
See all newsSigilon Therapeutics Inc reports results for the quarter ended in June - Earnings Summary
Sigilon Therapeutics Inc expected to post a loss of $4.71 a share - Earnings Preview
U.S. STOCKS ON THE MOVE-Micron, Greenbrier, Immunome
Sigilon jumps on Eli Lilly's buyout deal to expand diabetes treatments
U.S. STOCKS ON THE MOVE-Sigilon, Netflix, RenovoRx